FDMT compared with PCVX: revenue, margins and what each company keeps, and the suppliers and customers both name

FDMT4D Molecular Therapeutics, Inc.

Mkt capRevenueRevenue

PCVXVaxcyte, Inc.

Mkt capRevenueRevenue

Compare

FDMT4D Molecular Therapeutics, Inc.

PCVXVaxcyte, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

FDMT

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±30.9%▲+4.64%×0.15

May 8 '26±34.6%▲+2.11%×0.06

Q1 FY26±38.6%▲+4.91%×0.13

Jan 7 '26±18.7%▲+8.07%×0.43

PCVX

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±8.6%▲+5.31%×0.62

May 7 '26±7.2%▼−9.84%×1.36

= impliedFDMT realized, solidPCVX realized, hatchedOne scale, both sides: full bar = 39%× = |realized| ÷ impliedSource: market data

Q1 FY26

±10.5%

▲+2.75%

×0.27

Nov 5 '25±16.7%▼−2.49%×0.15

FDMT4D Molecular Therapeutics, Inc.

11.88· pre 11.34· delayed

Mkt cap$820.7MRevenue$4MQ2 FY26

PCVXVaxcyte, Inc.

60.75· pre 60.76· delayed

Pre-marketNov 2 '26delayed

Mkt cap$9.0BRevenue—

Compare

Pre-marketNov 2 '26delayed

FDMT4D Molecular Therapeutics, Inc.

PCVXVaxcyte, Inc.

11.88pre 11.34delayed

Price

60.75pre 60.76delayed

$820.7M

Mkt cap

$9.0B

Q2 FY26$4M

Revenue

—

FDMT11.88vsPCVX60.75Pre-marketNov 2 '26delayed